Rona Therapeutics Submits IND for RN3161 in 2025, Focusing on INHBE siRNA as Potential Obesity Treatment
Rona Therapeutics Submits Novel siRNA Treatment for Obesity Management
Rona Therapeutics, a company renowned for its innovative innovation in RNAi medicines, has taken a significant step forward in the fight against obesity. The company has submitted RN3161, a novel siRNA targeting the INHBE gene, to the Australian Human Research Ethics Committee (HREC).
RN3161 is a proprietary GalNAc-conjugated siRNA designed for adults with overweight and obesity. Its primary goal is to target the INHBE gene, found in the liver, which produces Activin E, a protein that helps control fat metabolism.
The submission of RN3161 underscores Rona's consistent excellence in advancing innovative innovation from the lab to the bedside. Stella Shi, CEO of Rona Therapeutics, suggested that RN3161 could maintain high-quality weight loss even in the GLP-1 era.
In preclinical trials, RN3161 has demonstrated more than 90% INHBE mRNA knockdown in monkeys with a low single dose. This potent gene silencing allows for infrequent dosing, offering better adherence and weight loss maintenance.
RN3161's long-lasting gene silencing supports Q6M to Q12M dosing, enhancing patient adherence and suitability for long-term obesity management. Moreover, RN3161 targets INHBE to reduce fat while preserving lean mass, setting it apart from existing treatments.
People with certain INHBE gene changes have been found to have better fat distribution, healthier cholesterol levels, and lower risks of type 2 diabetes or heart disease. This suggests that RN3161 could enhance the metabolic benefits associated with fat loss.
Alex M. DePaoli, CMO of Rona Therapeutics, stated that the HREC submission of RN3161 marks an exciting step in advancing a novel therapeutic for obesity. This milestone renews Rona's mission to bring innovative and durable therapies to patients worldwide.
RN3161 is the fourth clinical candidate from Rona's proprietary GAIATM platform. Stella Shi, CEO, is committed to translating cutting-edge siRNA technologies into therapies in multiple areas. The HREC submission of RN3161 reflects Rona's ambition to reshape the obesity treatment paradigm for healthier weight loss.
While the search results did not provide information about the leader of Rona Therapeutics or details on the submission of RN3161 to the Australian Human Research Ethics Committee, one thing is clear: Rona Therapeutics is making strides in the development of innovative innovation for obesity. With RN3161, they aim to offer a solution that maintains high-quality weight loss, enhances metabolic benefits, and preserves muscle mass, setting a new standard in obesity treatment.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
